Metabolic Weekly
Research

Beyond GLP-1: GIP's Crucial Role in Tirzepatide's Weight Loss Success

The landscape of metabolic disease treatment is undergoing a profound transformation, spearheaded by therapies that leverage the body’s innate hormonal systems. Among these, tirzepatide stands out as a groundbreaking medication, not just for its efficacy but for its unique dual mechanism targeting both GLP-1 and GIP receptors. This article delves into the often-underestimated role of Glucose-dependent Insulinotropic Polypeptide (GIP) in weight loss, explaining how its synergistic action with GLP-1 contributes to tirzepatide's remarkable success in managing obesity and type 2 diabetes. Discover why understanding GIP is key to appreciating the next generation of metabolic therapies.

Priya Mehra

Priya Mehra

Medical Science Writer

Dr. Cormac Ellery

Medically Reviewed by

Dr. Cormac Ellery

Clinical Pharmacologist, Cleveland Clinic

Published March 19, 2026 · 7 min read

Considering Tirzepatide? Explore Your Options

If the science behind tirzepatide's dual mechanism has piqued your interest in advanced weight loss solutions, Remedy Meds provides trusted information and access to consultations. Understand how these innovative therapies could support your health goals.

Connect with Remedy Meds →

The landscape of metabolic disease treatment is undergoing a profound transformation, spearheaded by therapies that leverage the body’s innate hormonal systems. Among these, tirzepatide stands out, a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its efficacy is particularly relevant given the alarming prevalence of obesity, affecting 42.4% of US adults, a figure reported by the Centers for Disease Control and Prevention (CDC) in their 2017-2018 National Health

Related

Ready to Start Your GLP-1 Journey?

Connect with a licensed provider who can prescribe compounded semaglutide — starting at a fraction of brand-name cost.

Check Your Eligibility →

*Affiliate link. We may earn a commission at no extra cost to you.

Priya Mehra

Priya Mehra

Medical Science Writer

Health journalist covering GLP-1 medications, metabolic health, and the telehealth industry. All articles are fact-checked and medically reviewed.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult with a qualified healthcare provider before starting any medication. Last updated: March 19, 2026.